Cargando…

Targeting Apoptosis Signaling Pathways for Anticancer Therapy

Treatment approaches for cancer, for example chemotherapy, radiotherapy, or immunotherapy, primarily act by inducing cell death in cancer cells. Consequently, the inability to trigger cell death pathways or alternatively, evasion of cancer cells to the induction of cell death pathways can result in...

Descripción completa

Detalles Bibliográficos
Autor principal: Fulda, Simone
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Research Foundation 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3356026/
https://www.ncbi.nlm.nih.gov/pubmed/22655234
http://dx.doi.org/10.3389/fonc.2011.00023
_version_ 1782233483218780160
author Fulda, Simone
author_facet Fulda, Simone
author_sort Fulda, Simone
collection PubMed
description Treatment approaches for cancer, for example chemotherapy, radiotherapy, or immunotherapy, primarily act by inducing cell death in cancer cells. Consequently, the inability to trigger cell death pathways or alternatively, evasion of cancer cells to the induction of cell death pathways can result in resistance of cancers to current treatment protocols. Therefore, in order to overcome treatment resistance a better understanding of the underlying mechanisms that regulate cell death and survival pathways in cancers and in response to cancer therapy is necessary to develop molecular-targeted therapies. This strategy should lead to more effective and individualized treatment strategies that selectively target deregulated signaling pathways in a tumor type- and patient-specific manner.
format Online
Article
Text
id pubmed-3356026
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Frontiers Research Foundation
record_format MEDLINE/PubMed
spelling pubmed-33560262012-05-31 Targeting Apoptosis Signaling Pathways for Anticancer Therapy Fulda, Simone Front Oncol Oncology Treatment approaches for cancer, for example chemotherapy, radiotherapy, or immunotherapy, primarily act by inducing cell death in cancer cells. Consequently, the inability to trigger cell death pathways or alternatively, evasion of cancer cells to the induction of cell death pathways can result in resistance of cancers to current treatment protocols. Therefore, in order to overcome treatment resistance a better understanding of the underlying mechanisms that regulate cell death and survival pathways in cancers and in response to cancer therapy is necessary to develop molecular-targeted therapies. This strategy should lead to more effective and individualized treatment strategies that selectively target deregulated signaling pathways in a tumor type- and patient-specific manner. Frontiers Research Foundation 2011-08-29 /pmc/articles/PMC3356026/ /pubmed/22655234 http://dx.doi.org/10.3389/fonc.2011.00023 Text en Copyright © 2011 Fulda. http://www.frontiersin.org/licenseagreement This is an open-access article subject to a non-exclusive license between the authors and Frontiers Media SA, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and other Frontiers conditions are complied with.
spellingShingle Oncology
Fulda, Simone
Targeting Apoptosis Signaling Pathways for Anticancer Therapy
title Targeting Apoptosis Signaling Pathways for Anticancer Therapy
title_full Targeting Apoptosis Signaling Pathways for Anticancer Therapy
title_fullStr Targeting Apoptosis Signaling Pathways for Anticancer Therapy
title_full_unstemmed Targeting Apoptosis Signaling Pathways for Anticancer Therapy
title_short Targeting Apoptosis Signaling Pathways for Anticancer Therapy
title_sort targeting apoptosis signaling pathways for anticancer therapy
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3356026/
https://www.ncbi.nlm.nih.gov/pubmed/22655234
http://dx.doi.org/10.3389/fonc.2011.00023
work_keys_str_mv AT fuldasimone targetingapoptosissignalingpathwaysforanticancertherapy